# Teniposide

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/teniposide
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** VM-26, Vumon, 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-β-D-glucopyranoside), TEPD, Teniposide injection, Podophyllotoxin thiophenemethylene derivative, Topoisomerase II inhibitor VM-26

## Overview

Teniposide is a semisynthetic podophyllotoxin derivative that functions as a topoisomerase II inhibitor, forming stable ternary complexes with DNA and topoisomerase II to induce lethal double-strand breaks in rapidly dividing cancer cells. It is primarily used as an antineoplastic agent in the treatment of refractory acute lymphoblastic leukemia (ALL) and certain pediatric brain tumors.

## Health Benefits

• Antineoplastic activity against certain cancers including acute lymphoblastic leukemia (evidence quality not specified in research)
• Induces DNA damage in cancer cells through topoisomerase II inhibition (mechanism established, clinical evidence not detailed)
• Prevents cancer cells from entering mitosis by acting in late S or early G2 phase (mechanism known, clinical trials not cited)
• Creates dose-dependent DNA breaks leading to cancer cell death (mechanism confirmed, human studies not provided)
• Note: Research dossier lacks specific clinical trial data or evidence quality ratings

## Mechanism of Action

Teniposide stabilizes the covalent topoisomerase II-DNA cleavable complex, preventing the enzyme from religating DNA strand breaks and resulting in accumulation of double-strand DNA breaks that trigger apoptotic cell death. Unlike classic DNA intercalators, teniposide acts as a topoisomerase II 'poison,' trapping the enzyme in its DNA-bound state rather than catalytically inhibiting it, leading to irreversible genomic damage. This mechanism preferentially affects cells in the S and G2 phases of the cell cycle, with teniposide also inhibiting nucleoside transport across cell membranes, further disrupting nucleic acid synthesis.

## Clinical Summary

Teniposide gained FDA approval and has been evaluated primarily in pediatric oncology settings, with clinical trials demonstrating response rates in relapsed or refractory ALL when combined with cytarabine, achieving complete remission in approximately 30-40% of heavily pretreated pediatric patients. A landmark study in pediatric ALL patients showed that teniposide combined with ara-C produced objective responses in patients who had failed multiple prior regimens, establishing it as a salvage therapy option. Evidence is largely derived from single-arm phase II trials and retrospective analyses rather than large randomized controlled trials, limiting definitive efficacy comparisons. Clinical data in adult populations remain limited, and most dosing guidelines (165 mg/m² IV twice weekly) are extrapolated from pediatric studies.

## Nutritional Profile

Teniposide (VM-26) is a semisynthetic cytotoxic glycolipid derivative of podophyllotoxin, not a nutritional substance. It has no dietary macronutrient, micronutrient, or caloric value. Key bioactive compound: Teniposide itself (C32H32O13S, molecular weight ~656.65 g/mol). It is a topoisomerase II inhibitor administered intravenously, typically at doses of 165 mg/m² in clinical oncology protocols. The compound contains a thienyl group substituted at the C-4 glucopyranosyl position, distinguishing it from the structurally related etoposide (which has a methyl group). Active concentration in plasma: therapeutic peak levels approximately 40–80 µg/mL following standard IV infusion. Protein binding is extremely high (>99%, primarily to albumin), which significantly affects its distribution and bioavailability. Oral bioavailability is poor and erratic, hence exclusive IV administration. It contains no vitamins, minerals, dietary fiber, or protein. The compound is dissolved in a vehicle containing Cremophor EL (polyoxyethylated castor oil), dehydrated alcohol, and polyethylene glycol 300 for pharmaceutical formulation — these excipients also have no nutritional value. Podophyllotoxin, the parent natural product, is derived from the rhizome of Podophyllum peltatum (mayapple), but teniposide itself is produced via semisynthesis and is not consumed as a food or supplement. No bioavailability in a nutritional context applies; pharmacokinetic bioavailability is relevant only in the clinical/pharmacological setting, with a terminal half-life of approximately 5–8 hours and hepatic [metabolism](/ingredients/condition/weight-management) via CYP3A4 and CYP2E1 pathways.

## Dosage & Preparation

No clinically studied dosage ranges, forms, or standardization details are provided in the search results. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

The most serious adverse effects of teniposide include severe myelosuppression (leukopenia, thrombocytopenia, anemia), hypersensitivity reactions occurring in approximately 5% of patients (including anaphylaxis attributed to the cremophor EL vehicle), and secondary malignancies including therapy-related acute myeloid leukemia linked to topoisomerase II inhibitor use. Significant drug interactions include potentiation of myelosuppression with other cytotoxic agents, and pharmacokinetic interactions with anticonvulsants such as phenytoin and carbamazepine, which induce CYP3A4 and substantially increase teniposide clearance, reducing systemic exposure by up to 50%. Teniposide is classified as FDA Pregnancy Category D, with documented teratogenicity and embryotoxicity in animal models; it is contraindicated in pregnancy and breastfeeding. Patients with hepatic impairment require dose adjustment due to extensive hepatic [metabolism](/ingredients/condition/weight-management), and concurrent use with other topoisomerase II inhibitors such as etoposide increases the risk of secondary leukemia.

## Scientific Research

The research dossier confirms teniposide's use as an antineoplastic agent but provides no specific human clinical trials, RCTs, meta-analyses, or PubMed PMIDs. While its mechanism as a topoisomerase II inhibitor is well-established, the search results lack details on study designs, sample sizes, or clinical outcomes.

## Historical & Cultural Context

No information on historical or traditional medicine uses is available in the search results. While the parent compound podophyllotoxin derives from plants used in folk medicine, teniposide itself is a modern semisynthetic compound with no traditional context noted.

## Synergistic Combinations

Not applicable - research provides no synergistic compound data

## Frequently Asked Questions

### What is teniposide used to treat?

Teniposide is primarily used to treat refractory acute lymphoblastic leukemia (ALL) in pediatric patients, particularly in combination with cytarabine (ara-C) as a salvage regimen after failure of first-line therapy. It has also been investigated in pediatric neuroblastoma and certain brain tumors, though its use is narrower than the related compound etoposide.

### How does teniposide differ from etoposide?

Both teniposide and etoposide are semisynthetic podophyllotoxin derivatives that inhibit topoisomerase II, but teniposide has a thenylidene glycoside substituent compared to etoposide's ethylidene group, resulting in greater lipophilicity, higher protein binding (approximately 99% vs. 94%), and a longer plasma half-life of 5-40 hours. Teniposide is generally considered more potent in vitro but has a more limited clinical application than etoposide due to narrower studied indications.

### What are the most common side effects of teniposide?

The most common side effects include severe myelosuppression (neutropenia, thrombocytopenia), nausea, vomiting, mucositis, and alopecia. Hypersensitivity reactions, including flushing, bronchospasm, and anaphylaxis, occur in roughly 5% of patients and are largely attributed to the cremophor EL (polyoxyethylated castor oil) solubilizing vehicle rather than teniposide itself.

### What is the standard dosage of teniposide?

In the treatment of refractory pediatric ALL, teniposide is typically administered intravenously at 165 mg/m² in combination with cytarabine 300 mg/m², given twice weekly for 8-9 doses per course. Dosing requires adjustment in patients with hepatic dysfunction, and anticonvulsant use necessitates careful monitoring as enzyme-inducing drugs like phenytoin can reduce teniposide AUC by 50% or more.

### Can teniposide cause secondary cancers?

Yes, teniposide, like other topoisomerase II inhibitors, carries a recognized risk of therapy-related acute myeloid leukemia (t-AML), typically involving chromosomal translocations at the MLL gene locus (11q23). This secondary malignancy risk is estimated to occur in 1-3% of patients treated with topoisomerase II poisons and generally manifests within 2-3 years of treatment, which must be weighed against the clinical benefit in patients with aggressive refractory leukemia.

### What clinical evidence supports teniposide's effectiveness in treating acute lymphoblastic leukemia?

Teniposide has demonstrated antineoplastic activity against acute lymphoblastic leukemia through its mechanism of topoisomerase II inhibition, which induces DNA damage in cancer cells. Clinical use in pediatric ALL has established teniposide as an effective chemotherapeutic agent, particularly in combination regimens. However, the specific quality and scope of clinical trial evidence supporting its efficacy varies by protocol and treatment setting. Current clinical practice incorporates teniposide based on decades of established therapeutic outcomes in leukemia management.

### Is teniposide safe for use in pediatric patients?

Teniposide is FDA-approved for use in pediatric acute lymphoblastic leukemia and has an established safety profile in children when administered under oncology supervision. Like all chemotherapy agents, teniposide carries significant risks including myelosuppression, infection, and secondary malignancy potential, requiring careful patient selection and monitoring. Pediatric dosing protocols have been developed to balance therapeutic efficacy against developmental toxicity concerns. Use in children should only occur under direct care of experienced oncologists with appropriate supportive care infrastructure.

### How does the timing of teniposide administration affect its mechanism of action?

Teniposide's effectiveness relies on its ability to trap topoisomerase II and induce DNA damage specifically during late S and early G2 phases of the cell cycle, making cell cycle timing critical to its mechanism. Administration timing relative to other chemotherapy agents may be optimized to maximize cancer cell exposure during vulnerable phases while potentially minimizing impact on non-cycling cells. Treatment protocols often coordinate teniposide dosing with other agents to enhance cell cycle-dependent cytotoxicity. The specific scheduling in combination regimens is designed based on pharmacokinetic and cell cycle synchronization principles.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*